Key terms
About ARVN
Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer, ARV-471, and ARV-766, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company was founded in February 2013 and is headquartered in New Haven, CT.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest ARVN news
Apr 24
4:41pm ET
Arvinas appoints Randy Teel Chief Business Officer
Apr 16
2:40am ET
Analysts’ Top Healthcare Picks: Quanterix (QTRX), Intuitive Surgical (ISRG)
Apr 15
12:50pm ET
Cantor Fitzgerald biotech/biopharma analysts analyst/industry conference call
Apr 15
11:49am ET
Cantor Fitzgerald biotech/biopharma analysts analyst/industry conference call
Apr 15
11:49am ET
Cantor Fitzgerald biotech/biopharma analysts analyst/industry conference call
Apr 15
6:47am ET
Arvinas price target lowered to $87 from $90 at H.C. Wainwright
Apr 12
8:29am ET
Piper Sandler Sticks to Their Buy Rating for Arvinas Holding Company (ARVN)
Apr 12
7:10am ET
Analysts Offer Insights on Healthcare Companies: Prime Medicine, Inc. (PRME), Arvinas Holding Company (ARVN) and Viridian Therapeutics (VRDN)
Apr 11
1:05pm ET
Buy Rating Affirmed for Arvinas Amid Strategic Novartis Deal and Growth Potential
Apr 11
7:05am ET
Arvinas enters exclusive strategic license agreement with Novartis for ARV-766
Apr 03
7:10am ET
Wall Street Analysts Are Bullish on Top Healthcare Picks
Mar 18
5:04pm ET
Arvinas Appoints New Chief Medical Officer for Clinical Programs
Mar 18
4:46pm ET
Arvinas names Noah Berkowitz as Chief Medical Officer
Mar 01
12:58am ET
Arvinas Holding Company: A Buy Rating on Strong Clinical Pipeline and Promising Trial Outcomes
Feb 29
5:52am ET
Arvinas price target raised to $60 from $26 at Barclays
Feb 28
8:46am ET
Arvinas price target raised to $59 from $33 at Wedbush
Feb 28
7:36am ET
Arvinas Holding Company: Buy Rating Backed by Promising Breast Cancer Therapy and Strategic Expansion into Parkinson’s Disease Treatment
Feb 28
7:30am ET
Piper Sandler Keeps Their Buy Rating on Arvinas Holding Company (ARVN)
Feb 28
5:40am ET
Buy Rating Affirmed for Arvinas Holding Company Amid Strong Drug Candidate Prospects and Robust Financial Health
Feb 27
4:23pm ET
Arvinas VERITAC-2 trial timelines not changed, says Oppenheimer
Feb 27
3:46pm ET
Arvinas Holding Company: A Strong Buy on Robust Clinical Data and Strategic Trial Advancements
Feb 27
7:02am ET
Arvinas expects cash to fund operations into 2027
Feb 27
7:01am ET
Arvinas reports Q4 EPS ($2.53), consensus ($1.27)
Feb 20
4:27pm ET
Arvinas CFO Sean Cassidy to Resign, Interim Successor Named
Feb 20
4:26pm ET
Arvinas announces resignation of CFO Sean Cassidy
Feb 20
7:12am ET
Arvinas announces first-in-human dosing of ARV-102
Feb 14
8:22am ET
Carrick announces first patient dosed in trial of samuraciclib, vepdegestrant
Feb 14
7:35am ET
Arvinas downgraded to Neutral from Buy at Citi
Feb 08
5:46am ET
Arvinas Holding Company: A Promising Buy Amidst Progressive Drug Development and Strategic Collaborations
Feb 08
5:26am ET
Goldman Sachs Predicts at Least 45% Rally for These 2 ‘Strong Buy’ Stocks — Here’s Why They Have Solid Upside
Feb 06
6:49am ET
Arvinas, Pfizer: FDA grants Fast Track designation for ARV-471
No recent press releases are available for ARVN
ARVN Financials
Key terms
Ad Feedback
ARVN Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ARVN Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range